SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at the annual meeting of the American Association for Cancer Research demonstrate that Marshall Edwards, Inc.'s investigational drug candidate triphendiol (NV-196) induces apoptosis in pancreatic and bile duct cancer cell lines, and also retards tumor proliferation in animal models of both indications. Of significance, triphendiol also potently sensitizes pancreatic and bile duct cancer cell lines and xenograft tumors to the standard of care drug, gemcitabine. These data were presented by Ewan Tytler, PhD, Assistant Professor, Division of General Surgery, Gastroinstestinal Section, University of Alabama at Birmingham (UAB), as part of a "late breaking" poster session.
